See more : Bal Pharma Limited (BALPHARMA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Senseonics Holdings, Inc. (SENS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senseonics Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- FuelCell Energy, Inc. (FCEL) Income Statement Analysis – Financial Results
- Xingda International Holdings Limited (XNGIF) Income Statement Analysis – Financial Results
- Commerce One Holdings Inc. (4496.T) Income Statement Analysis – Financial Results
- Securitas AB (publ) (SECU-B.ST) Income Statement Analysis – Financial Results
- Times Guaranty Limited (TIMESGTY.BO) Income Statement Analysis – Financial Results
Senseonics Holdings, Inc. (SENS)
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.39M | 16.39M | 13.68M | 4.95M | 21.30M | 18.91M | 6.37M | 332.00K | 38.00K | 0.00 | 17.00K |
| Cost of Revenue | 19.30M | 13.66M | 14.49M | 22.32M | 40.75M | 27.06M | 9.76M | 660.00K | 118.00K | 0.00 | 5.00K |
| Gross Profit | 3.09M | 2.73M | -811.00K | -17.37M | -19.45M | -8.15M | -3.39M | -328.00K | -80.00K | 0.00 | 12.00K |
| Gross Profit Ratio | 13.81% | 16.63% | -5.93% | -350.90% | -91.30% | -43.07% | -53.11% | -98.80% | -210.53% | 0.00% | 70.59% |
| Research & Development | 48.75M | 39.72M | 27.22M | 20.41M | 38.43M | 31.86M | 30.74M | 26.35M | 18.25M | 12.88M | 13.79M |
| General & Administrative | 0.00 | 0.00 | 21.54M | 20.80M | 23.23M | 19.84M | 15.34M | 13.02M | 9.81M | 5.73M | 5.01M |
| Selling & Marketing | 0.00 | 0.00 | 7.62M | 20.55M | 49.56M | 27.73M | 6.86M | 2.74M | 792.00K | 95.00K | 0.00 |
| SG&A | 29.94M | 31.63M | 29.15M | 41.35M | 72.78M | 47.57M | 22.19M | 15.76M | 10.60M | 5.82M | 5.01M |
| Other Expenses | 0.00 | -102.00K | -174.00K | -311.00K | -511.00K | -321.00K | 176.00K | 25.00K | 26.00K | 0.00 | 0.00 |
| Operating Expenses | 78.69M | 71.35M | 56.37M | 61.76M | 111.21M | 79.43M | 52.93M | 42.11M | 28.85M | 18.70M | 18.80M |
| Cost & Expenses | 97.99M | 85.02M | 70.86M | 84.08M | 151.96M | 106.49M | 62.69M | 42.77M | 28.85M | 18.70M | 18.81M |
| Interest Income | 5.36M | 1.82M | 243.00K | 175.00K | 1.93M | 2.00M | 135.00K | 80.00K | 9.00K | 0.00 | 10.00K |
| Interest Expense | 11.11M | 18.70M | 16.72M | 16.17M | 12.20M | 8.28M | 3.10M | 1.60M | 1.10M | 191.00K | 0.00 |
| Depreciation & Amortization | 1.28M | 985.00K | 1.24M | 1.14M | 1.00M | 270.00K | 227.27K | 155.00K | 118.00K | 189.00K | 220.00K |
| EBITDA | -48.01M | 161.81M | -284.52M | -157.86M | -99.41M | -85.42M | -55.77M | -42.17M | -28.66M | -18.51M | -18.57M |
| EBITDA Ratio | -214.40% | -408.23% | -417.65% | -1,859.91% | -622.43% | -454.17% | -875.18% | -12,702.71% | -75,418.42% | 0.00% | -109,229.41% |
| Operating Income | -75.60M | -68.63M | -57.18M | -79.13M | -130.66M | -87.58M | -56.31M | -42.43M | -28.81M | -18.70M | -18.79M |
| Operating Income Ratio | -337.66% | -418.74% | -418.15% | -1,598.91% | -613.41% | -463.06% | -883.62% | -12,781.02% | -75,821.05% | 0.00% | -110,523.53% |
| Total Other Income/Expenses | 15.21M | 210.75M | -245.29M | -96.04M | 15.11M | -6.39M | -2.79M | -1.50M | -1.07M | -183.00K | 10.00K |
| Income Before Tax | -60.39M | 142.12M | -302.48M | -175.17M | -115.55M | -93.97M | -59.10M | -43.93M | -29.88M | -18.89M | -18.78M |
| Income Before Tax Ratio | -269.73% | 867.16% | -2,211.88% | -3,539.46% | -542.46% | -496.86% | -927.37% | -13,231.93% | -78,623.68% | 0.00% | -110,464.71% |
| Income Tax Expense | 0.00 | 18.70M | 15.31M | 15.86M | 10.69M | 6.39M | 2.79M | 1.50M | 1.07M | 183.00K | 0.00 |
| Net Income | -60.39M | 142.12M | -317.78M | -191.02M | -126.23M | -93.97M | -59.10M | -43.93M | -29.88M | -18.89M | -18.78M |
| Net Income Ratio | -269.73% | 867.16% | -2,323.81% | -3,859.85% | -592.62% | -496.86% | -927.37% | -13,231.93% | -78,623.68% | 0.00% | -110,464.71% |
| EPS | -0.11 | 0.30 | -0.75 | -0.84 | -0.67 | -0.60 | -0.51 | -0.49 | -0.33 | -9.89 | -24.66 |
| EPS Diluted | -0.11 | -0.11 | -0.75 | -0.84 | -0.67 | -0.60 | -0.51 | -0.49 | -0.33 | -9.89 | -24.66 |
| Weighted Avg Shares Out | 567.97M | 467.95M | 422.32M | 227.91M | 188.75M | 157.43M | 115.98M | 89.24M | 91.56M | 1.91M | 761.63K |
| Weighted Avg Shares Out (Dil) | 567.97M | 618.21M | 422.32M | 227.91M | 188.75M | 157.43M | 115.98M | 89.24M | 91.56M | 1.91M | 761.63K |
Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that promising new data and...
Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association's 84th Scientific Sessions
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst...
Senseonics Holdings, Inc. to Participate in the Sidoti Small Cap Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Sidoti Small...
Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales
Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.
Senseonics Holdings, Inc. (SENS) Q1 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:11 PM ET Senseonics Holdings, Inc. (NYSE:SENS ) Q1 2024 Earnings Conference Call May 13, 2024, 16:30 AM ET Company Participants Tim Goodnow - President and CEO Rick Sullivan - CFO Jeff Ruiz -...
Senseonics Holdings, Inc. Reports First Quarter 2024 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31,...
Senseonics and Mercy Collaborate to Improve Diabetes Population Health Management
GERMANTOWN, Md. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitor (CGM) systems for people with diabetes, in partnership with our global commercial partner,...
Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a strategic partnership with Rimidi, a leading clinical...
Senseonics Holdings, Inc. to Participate in Upcoming Conferences
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming RBC Capital...
Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter...
Source: https://incomestatements.info
Category: Stock Reports